Navigation Links
Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine
Date:6/11/2008

stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.

Iomai announced on May 12 that it has entered into an agreement with Intercell AG in which Intercell will acquire Iomai for $6.60 a share.

Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about the patch vaccine being a prophylaxis for travelers' diarrhea, the timing for commencing Phase III studies, and bringing the product candidate to market; the potential size of the market for a travelers' diarrhea vaccine; the applicability of TCI technology to other pathogens; that, if approved, Iomai's vaccine would be the first available in the U.S.; and about the anticipated acquisition of Iomai by Intercell. Applicable risks and uncertainties include, among others, that Iomai may not be able to enroll sufficient numbers of patients in future clinical trials; that future clinical trials may not replicate results seen in the trial described in this press release; that Iomai may be unable to obtain the regulatory approval
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
5. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
6. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
7. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Research and ... "Global Ophthalmic Diagnostic Devices Market 2014-2018" report to ... About Ophthalmic Diagnostic Device ... to identify a defect or deficiency in the human ... ophthalmic disorders such as presbyopia, cataracts, glaucoma, retinal disorders, ...
(Date:7/25/2014)... NORTH CHICAGO, Ill., July 25, 2014 ... PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION ... RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ... quarter ended June 30, 2014. "This was ... and earnings per share above our original guidance and announced ...
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35
... JUPITER, Fla., Jan. 31, 2012 BioRestorative Therapies, Inc. ... into a License Agreement with Regenerative Sciences, LLC ("RS") with ... developed by RS. The treatment is an advanced stem cell ... buttock and leg pain, or numbness and tingling in the ...
... The report " In-Vitro Diagnostic ... (Major & Emerging Markets   -   G7, Japan & ... suggests, analyzes and studies the major market drivers, restraints, and ... World. Browse market data tables and ...
Cached Medicine Technology:BioRestorative Therapies Signs License Agreement for Stem Cell Disc/Spine Procedure 2BioRestorative Therapies Signs License Agreement for Stem Cell Disc/Spine Procedure 3MarketsandMarkets: Global In-Vitro Diagnostic (IVD) Market Expected to Reach $64 Billion by 2016 2MarketsandMarkets: Global In-Vitro Diagnostic (IVD) Market Expected to Reach $64 Billion by 2016 3
(Date:7/27/2014)... BC (PRWEB) July 27, 2014 Prominent ... recently announced their demonstration depicting the hamstring release procedure ... in Action Wellness Center in Vancouver and have years ... hamstring release procedure was carried out by the two ... purpose of the exercise is to release tight hamstrings ...
(Date:7/27/2014)... TX (PRWEB) July 27, 2014 ... on Global and Chinese Dutasteride (CAS 164656-23-9) industry. ... Dutasteride (CAS 164656-23-9) including its classification, application and ... China’s top manufacturers of Dutasteride (CAS 164656-23-9) listing ... share etc. , The report further analyzes quantitatively ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The European ... market in Europe with analysis and forecast of revenue. ... grow from around $509.4 million in 2013 to $657.1 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. It also provides ...
(Date:7/27/2014)... 2014 The European Bromine market report defines ... forecast of revenue. , Bromine market in European region comprises ... UK. Germany and France that forms a dominant share of ... in Europe. , Browse through the TOC of the ... in-depth analysis provided Browse through the TOC of the Europe ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Although ... Australia is restricted to two companies, heavy government ... IBISWorld industry analyst Spencer Little, “Demand for cigarettes ... to rising health concerns, frequent anti-smoking campaigns, increasing ... industry revenue is estimated to fall at a ...
Breaking Medicine News(10 mins):Health News:Renowned Vancouver Chiropractors Demonstrates Hamstring Release in Vancouver, BC 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4
... Results on Preoperative Chemotherapy in Early Breast Cancer ... than six cycles in women with early breast cancer ... data from a randomized controlled trial. Additionally, women who ... one drug combination did not benefit from switching to ...
... California Long-Term Care Reimbursement Act of 2004 increased nursing home ... according to a UCSF evaluation on the legislations impact. , ... homes increased by $590 million, or nearly 9 percent, to ... study, which was released today by researchers in the UCSF ...
... and shipping regions may be markedly worse than previously ... and shipping pollution is exacerbated when it combines with ... published in this weeks advance online edition of the ... University of Calgary chemistry professor Hans Osthoff report that ...
... is prevalent among people living with chronic diseases, such ... live normal lives, they must manage symptoms and treatments ... daily basis. Now, researchers from two universities have found ... their symptoms of depression and improve the overall quality ...
... 2008 Marianjoy has,recently named two new Vice ... Pyrcik is the new Vice President and the ... responsible for the planning and,implementation of all fundraising ... giving, major and planned giving,special events and special ...
... ... Contracted Contrast Media, WAYNE, N.J., April 8, ... announced today that,the company has been awarded a two-year contract ... injection available to members of the Amerinet network., Amerinet ...
Cached Medicine News:Health News:Other highlights in the April 8 JNCI 2Health News:Other highlights in the April 8 JNCI 3Health News:Other highlights in the April 8 JNCI 4Health News:2004 long-term care act raised costs and worsened care, study shows 2Health News:2004 long-term care act raised costs and worsened care, study shows 3Health News:Sea salt worsens coastal air pollution: study 2Health News:Increasing positive experiences decreases depression symptoms in patients with multiple sclerosis 2Health News:Marianjoy Names Two Vice Presidents 2Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 2Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 3Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: